Voyager Therapeutics (NASDAQ: VYGR) has appointed Andre Turenne to serve as president and CEO of the Cambridge, MA-based gene therapy developer. Turenne will succeed Steven Paul, who is retiring but will remain on Voyager’s board of directors. Turenne comes to Voyager from Sanofi (NYSE: SNY), where he was most recently senior vice president, global head, business development and licensing. Last year, Sanofi withdrew from a partnership on VY-AADC, Voyager’s gene therapy for Parkinson’s disease, after Voyager declined to change the 2015 deal and grant the pharma giant U.S. rights to the experimental treatment. The partnership remains intact for other Voyager gene therapies. The Parkinson’s treatment is ready to start Phase 2/3 clinical testing. Turenne will begin in his new position on July 16, when Paul retires.